FT819 SLE data: 10 patients show durable responses; expansion cohorts; pivotal study planned 2026

FATE THERAPEUTICS INC

10 SLE patients treated; 2 with lupus nephritis achieved CRR at 6 months; 1 in DORIS at 15 months.
No dose-limiting toxicities, low-grade CRS, no ICANS or GvHD; supports same-day discharge plans.
Initiated dose-expansion cohorts in AAV, IIM, and SSc; engaging FDA for registrational study design with pivotal study goal in 2026.
Approximately 600 cryopreserved FT819 bags in inventory available for patient treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.